Analysts expect Merus NV (NASDAQ:MRUS) to post earnings per share (EPS) of ($0.71) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Merus’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.61). Merus posted earnings of ($2.06) per share during the same quarter last year, which suggests a positive year over year growth rate of 65.5%. The business is expected to issue its next earnings report on Friday, April 27th.
On average, analysts expect that Merus will report full year earnings of ($4.02) per share for the current financial year, with EPS estimates ranging from ($4.02) to ($4.01). For the next fiscal year, analysts forecast that the firm will post earnings of ($3.83) per share, with EPS estimates ranging from ($4.22) to ($3.44). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Merus.
Merus (NASDAQ:MRUS) last issued its earnings results on Thursday, November 30th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.26). Merus had a negative return on equity of 119.36% and a negative net margin of 809.20%.
Shares of Merus (MRUS) opened at $18.83 on Monday. The stock has a market capitalization of $365.35 and a P/E ratio of -2.67. Merus has a 52 week low of $13.23 and a 52 week high of $33.63.
WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/29/zacks-analysts-anticipate-merus-nv-mrus-to-announce-0-71-earnings-per-share.html.
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.